Patents Assigned to National Research Council of Canada
  • Patent number: 9476887
    Abstract: Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: October 25, 2016
    Assignee: National Research Council of Canada
    Inventors: Jianbing Zhang, Tomoko Hirama
  • Patent number: 9475863
    Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula I: wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 25, 2016
    Assignee: National Research Council of Canada
    Inventors: Eleonora Altman, Blair A. Harrison, Vandana Chandan
  • Publication number: 20160287698
    Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 6, 2016
    Applicants: BROCK UNIVERSITY, NATIONAL RESEARCH COUNCIL CANADA
    Inventors: Hongbin YAN, Wangxue CHEN, Rhonda KUO LEE
  • Publication number: 20160289730
    Abstract: A method of selectively identifying live microorganisms in a sample involves contacting a sample suspected of containing a live microorganism of interest with a biomolecular precursor labeled with a reactive chemical label. The live microorganism of interest is grown under conditions that promote selective growth of the microorganism to permit the microorganism to utilize the labeled biomolecular precursor to synthesize labeled biomolecules on a cell surface of the live microorganism. Labeled live microorganisms are contacted with a reporter and/or capture element bearing a functional group that reacts with the reactive chemical label. The labeled live microorganism is analyzed to identify it. The method can specifically isolate live microorganisms from dead ones thereby reducing the possibility of false identification of contaminating microorganisms and is able to detect specific strains using tailored metabolites that are specific for a given microorganism.
    Type: Application
    Filed: November 25, 2014
    Publication date: October 6, 2016
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: John PEZACKI, Allison SHERRATT, Yanouchka ROULEAU
  • Patent number: 9458101
    Abstract: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 4, 2016
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Jack Tuszynski, Jonathan Y. Mane, John Torin Huzil, Boguslaw Tomanek, Dorota Bartusik
  • Patent number: 9442108
    Abstract: In a centrifugal microfluidic device for conducting capture assays, a microfluidic platform rotates in a plane of rotation and has at least one capture surface for immobilizing a target particle of interest in the device. The capture surface oriented so that it is not parallel to the plane of rotation of the device and is positionally fixed in the device during operation of the device. The centrifugal force arising from rotation of the device forces the target particles against the capture surface. Capture efficiency is independent of the rate of flow of the fluid and independent of the rate of rotation of the microfluidic platform.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: September 13, 2016
    Assignee: National Research Council of Canada
    Inventors: Liviu Clime, Xuyen Dai Hoa, Teodor Veres, Francois Normandin
  • Patent number: 9435490
    Abstract: A microfluidic valve operable to semi-permanently close a channel of a microfluidic device defined between a thermoplastic elastomer (TPE) film and a substrate operates employs a surface contact bond between the TPE and a wall of the channel. Thermomechanical release of the valve, tristate functionality, and repeated semi-permanent closure and release are demonstrated.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: September 6, 2016
    Assignee: National Research Council of Canada
    Inventors: Jean-Christophe Galas, Emmanuel Roy, Teodor Veres
  • Publication number: 20160250633
    Abstract: A composition made of at least 60 wt. % of a thermoplastic elastomer resin and additives that are solid at least from 0-50° C., that has a Shore A hardness that is less than about 50 bears a patterned surface, the pattern comprising at least one microfluidic channel having a cross-sectional dimension smaller than 100 microns is a substrate for forming a microfluidic device. The chief advantages of such compositions are: its ability to bond in a sealing manner to smooth surfaces of many different compositions, its ease of manufacture and microstructure patterning, and its general impermeability to liquids.
    Type: Application
    Filed: January 6, 2016
    Publication date: September 1, 2016
    Applicant: National Research Council of Canada
    Inventors: Emmanuel Roy, Teodor Veres
  • Publication number: 20160250634
    Abstract: A microfluidic system, particularly suited as a cell culture system, is provided having a single monolithic biocompatible substrate with both a surface having an ordered array of nano-scale elements required for plasmonic response monitoring and a network of microchannels for precisely controlling cellular environment. The system has the additional advantages of low-volume consumption, rapid low-cost fabrication of molds with easily interchangeable microfluidic channel layouts, amenability to mass production, and in situ label-free real-time detection of cellular response, viability, behavior and biomolecular binding using plasmonic techniques. A ratio of greater than 0.2 between the cross-sectional dimension and the spacing distance of the nano-scale elements is useful for plasmonic response monitoring.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Applicant: National Research Council of Canada
    Inventors: Lidija MALIC, Keith MORTON, Teodor VERES
  • Patent number: 9431612
    Abstract: The present invention is directed to methods for tailoring the work function of electrodes in organic electronics using interfacial modifiers comprising functionalized semiconducting polymers and/or small molecules.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 30, 2016
    Assignees: The Governors of the University of Alberta, National Research Council of Canada
    Inventors: Brian Worfolk, Qun Chen, Jillian Buriak
  • Publication number: 20160228387
    Abstract: Provided herein are compositions and methods for reducing neurogeneration in a patient suffering from Parkinson's Disease, comprising administration of a composition comprising CoQ10 and polyoxyethanyl-a-tocopherylsebacate (PTS). The compositions of the invention have been shown to penetrate the blood-brain barrier in mammals, thus effecting delivery of CoQ10 directly to brain tissue. Beneficial effects of the treatment have been observed at lower doses of CoQ10 than previously described.
    Type: Application
    Filed: October 10, 2014
    Publication date: August 11, 2016
    Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, UNIVERSITY OF WINDSOR
    Inventors: Marianna SIKORSKA, Jagdeep SANDHU, Siyaram PANDEY
  • Patent number: 9399704
    Abstract: A discrete nanostructure formed by a method comprising providing an aliphatic multi-block copolymer. The aliphatic multi-block copolymer includes at least one polyester block and at least one functionalized polycarbonate block. The aliphatic multi-block copolymer, a deprotonating agent and water are mixed to form an aqueous mixture. The aqueous mixture is maintained at a reaction temperature suitable to result in self-assembly of the multi-block copolymer into nanoparticles.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: July 26, 2016
    Assignees: XEROX CORPORATION, NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Andrew J. Myles, Karen A. Moffat, Valerie M. Farrugia, Jordan H. Wosnick
  • Patent number: 9399234
    Abstract: An apparatus and method for open-atmosphere flame based spraying employs a nozzle to preheat, pressurize and atomize a mechanically pumped reactive and flammable liquid solution through a small orifice or a nozzle and then a set of pilot flames to combust the spray. The liquid feedstock is preheated to a supercritical temperature before reaching the nozzle and is pressurized before spraying due to a reduced size of the outlet port of the feedstock flow channel relative to the inlet. A supplementary collimating, or sheathing, gas is supplied to the flow channel of the feedstock and both the feedstock and the supplementary gas are uniformly heated before spraying. This arrangement helps to avoid clogging of the nozzle and results in satisfactory control of the properties of the particulate products of the spraying procedure.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: July 26, 2016
    Assignee: National Research Council of Canada
    Inventors: Radenka Maric, Thomas P. K. Vanderhoek, Justin Michael Roller
  • Patent number: 9400957
    Abstract: A quantum device is provided that includes controllably quantum mechanically coupled dangling bonds extending from a surface of a semiconductor material. Each of the controllably quantum mechanically coupled dangling bonds has a separation of at least one atom of the semiconductor material. At least one electrode is provided for selectively modifying an electronic state of the controllably quantum mechanically coupled dangling bonds. By providing at least one additional electron within the controllably quantum mechanically coupled dangling bonds with the proviso that there exists at least one unoccupied dangling bond for each one additional electron present, the inventive device is operable at least to 293 degrees Kelvin and is largely immune to stray electrostatic perturbations. Room temperature operable quantum cellular automata and qubits are constructed therefrom.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 26, 2016
    Assignees: National Research Council of Canada, The Governors of the University of Alberta
    Inventors: Gino A. Dilabio, Robert A. Wolkow, Jason L. Pitters, Paul G. Piva
  • Patent number: 9394561
    Abstract: An enzyme useful for producing cyclic peptides from linear peptide precursors and a gene encoding the enzyme are described. The enzyme is particularly useful for producing segetalins from linear presegetalin precursors. The linear presegetalin precursors may be derived from other linear presegetalin precursors farther upstream in the biosynthetic synthesis of the segetalin.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 19, 2016
    Assignee: National Research Council of Canada
    Inventors: Carla Jann Siobhan Barber, Darwin Wilfred Reed, Janet Anne Condie, Sheila Diniwe Sherin Chiwocha, Patrick Smithers Covello
  • Patent number: 9371429
    Abstract: A polymer of formula (I): where: n is an integer from 10 to 5,000; m is an integer from 10 to 5,000; Ar1 and Ar3 are the same or different and are residues derived from a tetra-hydroxy aromatic monomer, the tetra-hydroxy aromatic monomer being wherein R is the same or different and is H or a C1-C8 alkyl, C2-C8 alkenyl or C3-C8 cycloalkyl group; and, Ar2 and Ar4 are the same or different and are residues derived from a tetra-halogenated aromatic monomer, the tetra-halogenated aromatic monomer being wherein X is F, Cl or Br, and R1 and R2 are the same or different and are wherein y is an integer from 1 to 8; with the proviso that when Ar1 is the same as Ar3 and Ar2 is the same as Ar4, R1 and R2 are not both —CN is useful as a material for gas separation, vapor separation, adsorbents or catalysis.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 21, 2016
    Assignee: National Research Council of Canada
    Inventors: Naiying Du, Michael D. Guiver, Gilles P. Robertson
  • Patent number: 9371371
    Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions (47-49) and any one of positions (67-71), based on Kabat numbering; in one example, the Cys may be introduced at positions (49) and (69), based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions (62-66), based on Kabat numbering; in one example, the Cys residues may be introduced at positions (48 and 64), based on Kabat numbering.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: June 21, 2016
    Assignee: National Research Council of Canada
    Inventors: Dae Young Kim, Jamshid Tanha
  • Publication number: 20160168210
    Abstract: Compounds of interest, for example active pharmaceutical ingredients, probes or inactive carriers, may be delivered to a site of interest by conjugating the compound of interest to a collagen-binding linear hairpin (CBLH) peptide to form a molecule of Formula (I) and then providing the molecule to the site of interest where the CBLH peptide binds to collagen at the site of interest thereby delivering the compound of interest to the site of interest.
    Type: Application
    Filed: October 18, 2013
    Publication date: June 16, 2016
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Feng NI, Ping XU, Sazzad HOSSAIN, Dmitri TOLKATCHEV, Louis-Philippe RICHER
  • Publication number: 20160161111
    Abstract: In a premix supply, for supplying a fuel and oxidizer gas into a combustion chamber for burning, the premix supply having a smaller diameter flow than the combustion chamber, the premix supply comprising at least one dielectric barrier discharge device (DBD) comprising two electrodes separated by a dielectric, improved flame stability limits may be provided for the adjacent combustor by the actuation of the DBD to induce ionic wind. Both electrodes may be provided in a single wall of the premix supply. The two electrodes may be arranged substantially upstream and downstream of each other. The electrodes may be arranged to generate an ionic wind preferentially directed in a direction of flow through the premix supply.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 9, 2016
    Applicant: National Research Council of Canada
    Inventor: Wajid Ali CHISHTY
  • Patent number: 9353382
    Abstract: Processes, vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs, the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 31, 2016
    Assignee: National Research Council of Canada
    Inventors: Yves Durocher, Martin Loignon